On August 27, ASCENTAGE rose 13.18% in regular trading, reaching HKD 37.26 per share, with turnover of HKD 167 million.

The rally was driven by a convergence of positive catalysts. The company reported H1 total revenue of RMB 302 million, up 29% year-over-year, with product sales reaching RMB 282 million, a 33% increase, powered by the dual-engine commercialization of olverembatinib and lisaftoclax. Guotai Haitong Securities initiated coverage with an Overweight rating and a target price of HKD 59.09, projecting full-year revenue of RMB 1.015 billion, representing approximately 77% year-over-year growth. Additionally, CICC maintained its Outperform rating with a HKD 45 target price. The company also recently appointed a Chief Business Officer and Chief Commercial Officer to accelerate global commercialization, while multiple global registrational Phase III trials continue to advance.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)